© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Semaglutide Shows Greater CVD Risk Reduction Than Tirzepatide in Adults With Obesity: Daily Dose
September 23, 2025
Your daily dose of the clinical news you may have missed.
Expanding the Obesity Treatment Toolbox: The Promise of Dual-Action Medications
September 22, 2025
Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.
Updated COVID-19 Vaccines Are Approved, But Population Restrictions Concern Experts
September 22, 2025
Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.
Pilot Trial Challenges Routine Steroid Use After Pediatric Anaphylaxis ED Discharge
September 22, 2025
Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.
Urine-Based Cervical Cancer Screening Evaluated in World's Largest Study
September 22, 2025
The new study, based in China, will validate urine-based genetic methylation testing which concentrates trace amounts of HPV DNA by more than 10,000 times.
FDA Approves Guselkumab as First IL-23 Inhibitor With Fully Subcutaneous Induction Regimen for Ulcerative Colitis
September 22, 2025
FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.
GLP-1 RAs May Reduce Risk for Cancer in Adults with Obesity: Daily Dose
September 22, 2025
Your daily dose of the clinical news you may have missed.
Cervical Cancer Screening in Primary Care: A Q&A with Family Physician Ada Stewart, MD
September 19, 2025
Explore essential insights on cervical cancer screening, patient engagement, and innovative self-collection methods this Gynecologic Cancer Awareness Month.
Elinzanetant Update: Phase 3 Findings Published in JAMA with PDUFA Date Set for October 26
September 19, 2025
If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.
FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group
September 19, 2025
Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.